---
layout: post
title: "东吴证券给予药明康德买入评级 Q1业绩符合预期 全年业绩高确定性+高增速"
date: 2022-04-26 15:13:32 +0800
categories: meirijingjixinwen
tags: 每日经济新闻新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.02359" data-code="02359|116|5" data-code2="02359|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.02359&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 02359_0" data-code="K 02359|116|5" data-code2="K 02359|116|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.603259" data-code="603259|1|1" data-code2="603259|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.603259&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 603259_0" data-code="K 603259|1|1" data-code2="K 603259|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p><span id="stock_1.601555"><a href="http://quote.eastmoney.com/unify/r/1.601555" class="keytip" data-code="1,601555">东吴证券</a></span><span id="quote_1.601555"></span>04月26日发布<span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>称，给予<span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>(603259.SH，最新价：102.45元)买入评级。评级理由主要包括：1)<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>维持高增长，前瞻性预案降低疫情影响；2)常规化学业务高增速，新分子业务加速放量；3)依托WIND一体化凭条，测试业务保持稳定增长；4)生物和ATU业务增长动能强，DDSU业务短期受到影响。风险提示：产能扩张不及预期，汇兑损益风险，新冠订单不及预期等。<br /></p><p>AI点评：<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>近一个月获得17份<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>研报关注，买入14家，平均目标价为160元，与最新价102.45元相比，高57.55元，目标均价涨幅56.17%。</p><p class="em_media">（文章来源：每日经济新闻）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204262359381766>

[返回每日经济新闻新闻](//finews.withounder.com/category/meirijingjixinwen.html)｜[返回首页](//finews.withounder.com/)